DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th. Get Our Latest Stock […]
More Stories
West Oak Capital LLC Acquires 3,109 Shares of iShares Core S&P 500 ETF (NYSEARCA:IVV)
West Oak Capital LLC raised its holdings in iShares Core S&P 500 ETF (NYSEARCA:IVV – Free Report) by 287.6% in...
Progyny (NASDAQ:PGNY) Shares Up 3.1% – Should You Buy?
Progyny, Inc. (NASDAQ:PGNY – Get Free Report)’s stock price shot up 3.1% on Wednesday . The stock traded as high...
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 6.7% – Here’s What Happened
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) traded down 6.7% on Wednesday . The company traded...
PayPal (NASDAQ:PYPL) Shares Down 0.3% – Here’s Why
PayPal Holdings, Inc. (NASDAQ:PYPL – Get Free Report)’s stock price traded down 0.3% during mid-day trading on Wednesday . The...
Invesco QQQ (NASDAQ:QQQ) Stock Price Up 0% – Here’s Why
Invesco QQQ (NASDAQ:QQQ – Get Free Report)’s share price shot up 0% during mid-day trading on Wednesday . The stock...
Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock
Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc purchased 21,021 shares of Zymeworks stock in a transaction...